Global law firm White & Case LLP has advised Inversago Pharma Inc., a clinical-stage biotech company with a unique portfolio of peripherally acting CB1 inverse agonists, on its series C funding of CAD 95 million (approximately US$70 million).
Proceeds from the financing, which was led by New Enterprise Associates, will be used to move Inversago’s lead program, INV-202, into a phase 2 clinical trial in diabetic kidney disease in Q4 2022. Additionally, the funds will accelerate Inversago’s other key programs currently in pre-clinical development, while establishing its leadership in the field of CB1 blockers.
The White & Case team was led by M&A partner James Hu (New York), M&A counsel Trevor Currie (Chicago) and M&A associate Victoria Richmond (New York), and included Capital Markets partner Era Anagnosti (Washington, DC) and Tax partner Scott Fryman (New York).
For more information please speak to your local media contact.